Literature DB >> 16626984

Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host.

Juan Diego Maya1, Bruce K Cassels, Patricio Iturriaga-Vásquez, Jorge Ferreira, Mario Faúndez, Norbel Galanti, Arturo Ferreira, Antonio Morello.   

Abstract

Current knowledge of the biochemistry of Trypanosoma cruzi has led to the development of new drugs and the understanding of their mode of action. Some trypanocidal drugs such as nifurtimox and benznidazole act through free radical generation during their metabolism. T. cruzi is very susceptible to the cell damage induced by these metabolites because enzymes scavenging free radicals are absent or have very low activities in the parasite. Another potential target is the biosynthetic pathway of glutathione and trypanothione, the low molecular weight thiol found exclusively in trypanosomatids. These thiols scavenge free radicals and participate in the conjugation and detoxication of numerous drugs. Inhibition of this key pathway could render the parasite much more susceptible to the toxic action of drugs such as nifurtimox and benznidazole without affecting the host significantly. Other drugs such as allopurinol and purine analogs inhibit purine transport in T. cruzi, which cannot synthesize purines de novo. Nitroimidazole derivatives such as itraconazole inhibit sterol metabolism. The parasite's respiratory chain is another potential therapeutic target because of its many differences with the host enzyme complexes. The pharmacological modulation of the host's immune response against T. cruzi infection as a possible chemotherapeutic target is discussed. A large set of chemicals of plant origin and a few animal metabolites active against T. cruzi are enumerated and their likely modes of action are briefly discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16626984     DOI: 10.1016/j.cbpa.2006.03.004

Source DB:  PubMed          Journal:  Comp Biochem Physiol A Mol Integr Physiol        ISSN: 1095-6433            Impact factor:   2.320


  80 in total

1.  Clinical aspects of Chagas disease and implications for novel therapies.

Authors:  Cristiane Menezes; Germano Carneiro Costa; Kenneth J Gollob; Walderez O Dutra
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

2.  Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from Trypanosoma cruzi.

Authors:  Fabrício Fredo Naciuk; Jéssica do Nascimento Faria; Amanda Gonçalves Eufrásio; Artur Torres Cordeiro; Marjorie Bruder
Journal:  ACS Med Chem Lett       Date:  2020-04-27       Impact factor: 4.345

3.  Induction of oxidative stress in Trypanosoma brucei by the antitrypanosomal dihydroquinoline OSU-40.

Authors:  Shanshan He; Alex Dayton; Periannan Kuppusamy; Karl A Werbovetz; Mark E Drew
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

4.  In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease.

Authors:  Alisson L Matsuo; Luis S Silva; Ana C Torrecilhas; Bruno S Pascoalino; Thiago C Ramos; Elaine G Rodrigues; Sergio Schenkman; Antonio C F Caires; Luiz R Travassos
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

5.  X-ray structure of 4,4'-dihydroxybenzophenone mimicking sterol substrate in the active site of sterol 14alpha-demethylase (CYP51).

Authors:  Ali Nasser Eddine; Jens P von Kries; Mikhail V Podust; Thulasi Warrier; Stefan H E Kaufmann; Larissa M Podust
Journal:  J Biol Chem       Date:  2008-03-26       Impact factor: 5.157

6.  Why does GM1 induce a potent beneficial response to experimental Chagas disease?

Authors:  S Cossy Isasi; C A Condat; G J Sibona
Journal:  HFSP J       Date:  2009-01-21

7.  Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma.

Authors:  Karin Melanie Cabanillas Stanchi; Gernot Bruchelt; Rupert Handgretinger; Ursula Holzer
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

8.  Autophagic elimination of Trypanosoma cruzi in the presence of metals.

Authors:  Laís Pessanha de Carvalho; Edésio José Tenório de Melo
Journal:  J Microbiol       Date:  2019-08-28       Impact factor: 3.422

9.  Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice.

Authors:  Rômulo Dias Novaes; Eliziária C Santos; Marli C Cupertino; Daniel S S Bastos; Jerusa M Oliveira; Thaís V Carvalho; Mariana M Neves; Leandro L Oliveira; André Talvani
Journal:  Parasitol Res       Date:  2015-04-28       Impact factor: 2.289

10.  Molecular Dynamics Simulations of Substrate Release from Trypanosoma cruzi UDP-Galactopyranose Mutase.

Authors:  Rodrigo Cossio-Pérez; Gustavo Pierdominici-Sottile; Pablo Sobrado; Juliana Palma
Journal:  J Chem Inf Model       Date:  2019-01-17       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.